State Street’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
State Street's LUCD Position: Q3 2026 in Review
State Street increased its Lucid Diagnostics (LUCD) stake by 0.2% in Q3 2026, buying an estimated $4.56K and bringing the position to 2,442,220 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3432.
State Street first reported a position in LUCD in Q4 2021 and has held it in 20 quarters since. The position peaked at $2.61M in Q2 2026. 82 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.
- State Street held 2,442,220 shares of Lucid Diagnostics worth $1.83M as of Q3 2026.
- State Street bought 4,883 Lucid Diagnostics shares in Q3 2026, an estimated $4.56K.
- Lucid Diagnostics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3432 holding.
- State Street first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 20 quarters since.
- State Street's Lucid Diagnostics position peaked at $2.61M in Q2 2026.
- 82 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.
Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.